Maxim Group Keeps Their Buy Rating on Moleculin Biotech (MBRX)


Maxim Group analyst Jason McCarthy maintained a Buy rating on Moleculin Biotech (MBRX) today and set a price target of $3. The company’s shares opened today at $1.35.

McCarthy noted:

“Moleculin announced that it has begun recruiting patients in its second clinical trial of Annamycin for the treatment of relapsed/refractory acute myeloid leukemia. This study is being conducted in Poland. We see this as a positive for the company.”

According to TipRanks.com, McCarthy is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -8.9% and a 28.3% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, ContraVir Pharmaceuticals Inc, and Sonoma Pharmaceuticals Inc.

Moleculin Biotech has an analyst consensus of Moderate Buy, with a price target consensus of $5.50.

See today’s analyst top recommended stocks >>

The company has a one-year high of $3.34 and a one-year low of $0.93. Currently, Moleculin Biotech has an average volume of 367.5K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Moleculin Biotech, Inc. is a clinical stage pharmaceutical company, which focuses on the development of oncology drug candidates. Its Annamycin product candidate helps in the treatment of relapsed or refractory acute myeloid leukemia.